<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03898024</url>
  </required_header>
  <id_info>
    <org_study_id>2019 SHR-1222</org_study_id>
    <nct_id>NCT03898024</nct_id>
  </id_info>
  <brief_title>Effects of SHR-1222 on Vascular Inflammatory Factors in Patients With Low Bone Mass</brief_title>
  <official_title>Effects of SHR-1222 on Vascular Inflammatory Factors in Patients With Low Bone Mass</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Second Xiangya Hospital of Central South University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Second Xiangya Hospital of Central South University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to investigate the effects of SHR-1222 on vascular inflammatory factors in&#xD;
      patients with low bone mass.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, total 50 patients with low bone mass will be enrolled and divided into 5 dose&#xD;
      groups. In the lowest dose group 6 subjects will be recruited, among whom 4 will receive&#xD;
      SHR-1222 and the other 2 will receive placebo. In each of the other 4 groups, 11 subjects&#xD;
      will be recruited, among whom 9 will be administered with SHR-1222 and the other 2 with&#xD;
      placebo.&#xD;
&#xD;
      Levels of nitric oxide (NO), Endothelin-1 (ET-1), plasminogen activator inhibitor-1 (PAI-1)&#xD;
      and hypersensitivity C-reactive protein (hs-CRP) will be detected in patients before and&#xD;
      after the SHR-1222 injection.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 15, 2019</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of serum nitric oxide (NO) change after the administration of SHR-1222</measure>
    <time_frame>Day0 before the administration and Day 2, 4, 7, 15, 29, 43, 57 after the administration</time_frame>
    <description>NO level will be detected by nitrite/nitrate assay (colorimetric).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of serum Endothelin-1 (ET-1) change after the administration of SHR-1222</measure>
    <time_frame>Day0 before the administration and Day 2, 4, 7, 15, 29, 43, 57 after the administration</time_frame>
    <description>ET-1 level will be detected by ELISA.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of serum plasminogen activator inhibitor-1 (PAI-1) change after the administration of SHR-1222</measure>
    <time_frame>Day0 before the administration and Day 2, 4, 7, 15, 29, 43, 57 after the administration</time_frame>
    <description>PAI-1 level will be detected by ELISA.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of serum hypersensitivity C-reactive protein (hs-CRP) change after the administration of SHR-1222</measure>
    <time_frame>Day0 before the administration and Day 2, 4, 7, 15, 29, 43, 57 after the administration</time_frame>
    <description>hs-CRP level will be detected by immunoturbidimetry assay.</description>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Osteoporosis, Osteopenia</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single subcutaneous injection of SHR-1222 dose 1 versus placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single subcutaneous injection of SHR-1222 dose 2 versus placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single subcutaneous injection of SHR-1222 dose 3 versus placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single subcutaneous injection of SHR-1222 dose 4 versus placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single subcutaneous injection of SHR-1222 dose 5 versus placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR-1222</intervention_name>
    <description>Pharmaceutical form: water injection; Route of administration: subcutaneous</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_label>Cohort 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Pharmaceutical form: water injection; Route of administration: subcutaneous</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_label>Cohort 5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed informed consent;&#xD;
&#xD;
          -  Male or postmenopausal female;&#xD;
&#xD;
          -  Age ≥45 and ≤59 years old;&#xD;
&#xD;
          -  The body mass index (BMI) ≥18.5kg/m2 and ≤28 kg/m2;&#xD;
&#xD;
          -  T value of areal bone mineral density on any lumbar spine (L1-L4) or collum&#xD;
             femoris&gt;-2.5 and &lt;-1;&#xD;
&#xD;
          -  The comprehensive physical examination is eligible or slightly abnormal but the&#xD;
             researchers determine no clinical implication;&#xD;
&#xD;
          -  No smoking, alcohol or drugs abuse.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any disease affecting bone metabolism;&#xD;
&#xD;
          -  Past medical history of cerebral infarction or cerebral arterial thrombosis;&#xD;
&#xD;
          -  Past medical history of myocardial infarction;&#xD;
&#xD;
          -  Administration of the following drugs within 6m: Hormone replacement therapy,&#xD;
             Calcitonin Parathyroid hormone (or any derivative), Supplemental Vitamin D&gt;1,000&#xD;
             IU/day, Glucocorticosteroids (inhaled or topical corticosteroids administered more&#xD;
             than 2 weeks before the enrollment date are allowed), Anabolic steroids, Calcitriol&#xD;
             and available analogues, thiazide diuretics;&#xD;
&#xD;
          -  Administration of the following drugs within 12m: Bisphosphonates, Fluoride for&#xD;
             osteoporosis;&#xD;
&#xD;
          -  A bone fracture within the previous 6 months;&#xD;
&#xD;
          -  A lumbar spine L1-L4 or femoral neck T-score ≤-2.5;&#xD;
&#xD;
          -  Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) or gamma pancreatic&#xD;
             acyl transferase (GGT) or total bilirubin, more than 1.5 x ULN during screening;&#xD;
&#xD;
          -  3 months prior to screening involved in any drug clinical subjects;&#xD;
&#xD;
          -  Subjects determined by the researchers have any food, dietary supplement or drugs that&#xD;
             affect SHR-1222 absorption, distribution, metabolism and excretion in 4 weeks prior to&#xD;
             screening or within 5 half-lives;&#xD;
&#xD;
          -  Serious infection, trauma or major surgery in 4 weeks prior to screening;&#xD;
&#xD;
          -  A surgery plan during the study;&#xD;
&#xD;
          -  Blood donation and transfusion in 3 months prior to screening;&#xD;
&#xD;
          -  Unstable thyroid dysfunction in 6 months prior to screening;&#xD;
&#xD;
          -  Human immunodeficiency virus antibody (HIV-ab), syphilis serological examination,&#xD;
             hepatitis b virus surface antigen (HBsAg), hepatitis c virus antibody (HCV-ab) were&#xD;
             positive;&#xD;
&#xD;
          -  Intolerant to venous blood collection;&#xD;
&#xD;
          -  A clinical history of drug allergy or a history of atopic allergic diseases (asthma,&#xD;
             urticaria, eczema dermatitis) or a known allergy to experimental or similar；&#xD;
&#xD;
          -  Subjects with any other situation should not be involved, which determined by the&#xD;
             researchers.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>59 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhiguang Zhou, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Second Xiangya Hospital of Central South University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhijie Dai, MD</last_name>
    <phone>8613548564211</phone>
    <email>daizj09@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Second Xiangya Hospital of Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410011</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhou Zhiguang, PhD</last_name>
      <phone>+8613873104348</phone>
      <email>zhouzg@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Cao Chuqing, MD</last_name>
      <phone>+8615073136917</phone>
      <email>csuccq@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Zhou Zhiguang, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cao Chuqing, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yang Shuting, BA</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 26, 2019</study_first_submitted>
  <study_first_submitted_qc>March 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 1, 2019</study_first_posted>
  <last_update_submitted>March 20, 2020</last_update_submitted>
  <last_update_submitted_qc>March 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Second Xiangya Hospital of Central South University</investigator_affiliation>
    <investigator_full_name>Zhiguang Zhou</investigator_full_name>
    <investigator_title>Director, Department of Endocrinology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Bone Diseases, Metabolic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

